Replies to post #244616 on Biotech Values

[TwoNE1]

re: Epipen: $AQST epinephrine sublingual film

Aquestive Therapeutics Announces Positive EPIPHAST II Trial Data for AQST-109 When Compared to EpiPen

AQST-109 median time to maximum concentration (Tmax) of 12 minutes was faster than EpiPen® Tmax of 22.5 minutes

AQST-109 repeat dosing provided significantly higher drug plasma concentrations with a Tmax of 8 minutes after administration

Changes in systolic blood pressure and heart rate were similar after a single dose of AQST-109 when compared to a single dose of EpiPen

End-of-Phase 2 meeting with FDA scheduled for fourth quarter 2022 and remaining clinical studies will commence thereafter

Source: https://finance.yahoo.com/news/aquestive-therapeutics-announces-positive-epiphast-110000982.html